Literature DB >> 19334714

Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.

Pijus K Mandal1, Donald Limbrick, David R Coleman, Garrett A Dyer, Zhiyong Ren, J Sanderson Birtwistle, Chiyi Xiong, Xiaomin Chen, James M Briggs, John S McMurray.   

Abstract

Signal transducer and activator of transcription 3 (n class="Gene">Stat3) is involved in aberrant growth and survival signals in malignant tumor cells and is a validated target for anticancer drug design. We are targeting its SH2 domain to prevent docking to cytokine and growth factor receptors and subsequent signaling. The amino acids of our lead phosphopeptide, Ac-pTyr-Leu-Pro-Gln-Thr-Val-NH(2), were replaced with conformationally constrained mimics. Structure-affinity studies led to the peptidomimetic, pCinn-Haic-Gln-NHBn (21), which had an IC(50) of 162 nM (fluorescence polarization), compared to 290 nM for the lead phosphopeptide (pCinn = 4-phosphoryloxycinnamate, Haic = (2S,5S)-5-amino-1,2,4,5,6,7-hexahydro-4-oxo-azepino[3,2,1-hi]indole-2-carboxylic acid). pCinn-Haic-Gln-OH was docked to the SH2 domain (AUTODOCK), and the two highest populated clusters were subjected to molecular dynamics simulations. Both converged to a common peptide conformation. The complex exhibits unique hydrogen bonding between Haic and Gln and Stat3 as well as hydrophobic interactions between the protein and pCinn and Haic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19334714      PMCID: PMC2735258          DOI: 10.1021/jm801491w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  65 in total

Review 1.  Progress in the development of inhibitors of SH2 domains.

Authors:  W L Cody; Z Lin; R L Panek; D W Rose; J R Rubin
Journal:  Curr Pharm Des       Date:  2000-01       Impact factor: 3.116

2.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

3.  Solid-phase synthesis of Stat3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics.

Authors:  Pijus K Mandal; Patricia A Heard; Zhiyong Ren; Xiaomin Chen; John S McMurray
Journal:  Bioorg Med Chem Lett       Date:  2006-11-06       Impact factor: 2.823

4.  Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains.

Authors:  Patrick T Gunning; William P Katt; Matthew Glenn; Khandaker Siddiquee; Khandaker Siddique; Joon S Kim; Richard Jove; Saïd M Sebti; James Turkson; Andrew D Hamilton
Journal:  Bioorg Med Chem Lett       Date:  2007-01-27       Impact factor: 2.823

5.  Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms.

Authors:  G Waksman; S E Shoelson; N Pant; D Cowburn; J Kuriyan
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

6.  In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.

Authors:  Sichuan Xi; William E Gooding; Jennifer Rubin Grandis
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

7.  Synthesis of a 5-methylindolyl-containing macrocycle that displays ultrapotent Grb2 SH2 domain-binding affinity.

Authors:  Zhen-Dan Shi; Kyeong Lee; Chang-Qing Wei; Lindsey R Roberts; Karen M Worthy; Robert J Fisher; Terrence R Burke
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

8.  Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif.

Authors:  Huang Shao; Xuejun Xu; Mary-Ann A Mastrangelo; Naijie Jing; Richard G Cook; Glen B Legge; David J Tweardy
Journal:  J Biol Chem       Date:  2004-02-13       Impact factor: 5.157

9.  Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.

Authors:  L Tong; T C Warren; J King; R Betageri; J Rose; S Jakes
Journal:  J Mol Biol       Date:  1996-03-01       Impact factor: 5.469

10.  Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide.

Authors:  R X Xu; J M Word; D G Davis; M J Rink; D H Willard; R T Gampe
Journal:  Biochemistry       Date:  1995-02-21       Impact factor: 3.162

View more
  25 in total

1.  Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.

Authors:  Carolyn C Arpin; Stephen Mac; Yanlin Jiang; Huiwen Cheng; Michelle Grimard; Brent D G Page; Malgorzata M Kamocka; Sina Haftchenary; Han Su; Daniel P Ball; David A Rosa; Ping-Shan Lai; Rodolfo F Gómez-Biagi; Ahmed M Ali; Rahul Rana; Helmut Hanenberg; Kagan Kerman; Kyle C McElyea; George E Sandusky; Patrick T Gunning; Melissa L Fishel
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

Authors:  Jianyong Chen; Longchuan Bai; Denzil Bernard; Zaneta Nikolovska-Coleska; Cindy Gomez; Jian Zhang; Han Yi; Shaomeng Wang
Journal:  ACS Med Chem Lett       Date:  2010-05-13       Impact factor: 4.345

3.  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Fengqin Gao; Zhen Lu; Zhiyong Ren; Rajagopal Ramesh; J Sanderson Birtwistle; Kumaralal K Kaluarachchi; Xiaomin Chen; Robert C Bast; Warren S Liao; John S McMurray
Journal:  J Med Chem       Date:  2011-04-26       Impact factor: 7.446

4.  Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.

Authors:  Michele S Redell; Marcos J Ruiz; Todd A Alonzo; Robert B Gerbing; David J Tweardy
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

5.  Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.

Authors:  Xiaomei Ren; Lei Duan; Qiang He; Zhang Zhang; Yi Zhou; Donghai Wu; Jingxuan Pan; Duanqing Pei; Ke Ding
Journal:  ACS Med Chem Lett       Date:  2010-09-07       Impact factor: 4.345

6.  Identification of a New Series of STAT3 Inhibitors by Virtual Screening.

Authors:  Kenji Matsuno; Yoshiaki Masuda; Yutaka Uehara; Hiroshi Sato; Ayumu Muroya; Osamu Takahashi; Takane Yokotagawa; Toshio Furuya; Tadashi Okawara; Masami Otsuka; Naohisa Ogo; Tadashi Ashizawa; Chie Oshita; Sachiko Tai; Hidee Ishii; Yasuto Akiyama; Akira Asai
Journal:  ACS Med Chem Lett       Date:  2010-07-13       Impact factor: 4.345

7.  Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.

Authors:  Murali K Urlam; Roberta Pireddu; Yiyu Ge; Xiaolei Zhang; Ying Sun; Harshani R Lawrence; Wayne C Guida; Saïd M Sebti; Nicholas J Lawrence
Journal:  Medchemcomm       Date:  2013-06       Impact factor: 3.597

Review 8.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

9.  A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Authors:  Edmond J Auzenne; Jim Klostergaard; Pijus K Mandal; Warren S Liao; Zhen Lu; Fengqin Gao; Robert C Bast; Fredika M Robertson; John S McMurray
Journal:  J Exp Ther Oncol       Date:  2012

Review 10.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.